Efficacy News and Research

RSS

African Wormwood Identified as Potential Weapon Against Drug-Resistant Tuberculosis

The mechanisms through which A. afra fights M. tuberculosis.

14 Oct 2024

Bacterial Gene Expression Drives the Evolution of Antibiotic Resistance

As strains of pathogens resistant to frontline antibiotics become more common worldwide, clinicians are more often turning to combination treatments that degrade this resistance as a first treatment option.

14 Oct 2024

CAR-NKT Cells Show Promise in Overcoming Solid Tumor Barriers

Chimeric antigen receptor T-cell therapy (CAR-T) has shown significant promise in the treatment of blood malignancies in the fight against cancer.

8 Oct 2024

Fighting Drug-Resistant TB with a Novel Antibiotic

A novel semi-synthetic molecule that produces significant activity against strains of Mycobacterium tuberculosis, including those that are resistant to drugs, can be generated from natural compounds according to a study published in the American Society for Microbiology journal Microbiology Spectrum.

4 Oct 2024

Aidian is Now An IVDR Certified Company

We are proud to announce that Aidian has successfully achieved IVDR (In Vitro Diagnostic Regulation) certification, which was granted by notified body TüV SüD Product Service GmbH.

From Aidian Oy 20 Sep 2024

ERGA Pilot Project Unites Scientists to Deliver High-Quality Genomes

The European Reference Genome Atlas (ERGA) has announced the outcome of its pilot project in a new article.

18 Sep 2024

Modified Nucleotides Boost saRNA Vaccine Efficacy and Protection Against SARS-CoV-2

Modified nucleotides like m5C in saRNA enhance vaccine efficacy, stability, and reduce inflammation, offering a promising approach for SARS-CoV-2 protection.

18 Sep 2024

Lipids Found to Play Key Role in Cancer Immune Evasion

Cancer cells seldom start off stealthy. Quite to the contrary, they announce their presence to the immune system by planting chemical red flags right on their membranes.

18 Sep 2024

Innovative Approach Supercharges T Cells by Transferring Healthy Mitochondria

Fighting cancer is exhausting for T cells. Hostile tumor microenvironments can drain their mitochondrial activity, leading to a condition known as T cell exhaustion.

16 Sep 2024

Developing Techniques for Imaging Biomolecules

Scientists are working to create quicker, more quantitative, and more publicly available methods of seeing biomolecules in living cells to speed up biotechnology discoveries, such as the production of lifesaving drugs.

11 Sep 2024

Breakthrough Nanoparticle Therapy Boosts Immune Response Against Aggressive Pancreatic Cancer

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in pancreatic ductal adenocarcinoma models.

9 Sep 2024

From Bone Regeneration to Heart Repair: Stem Cell Transplantation Paves the Way for New Medical Frontiers

Stem cell transplantation offers promising solutions for tissue regeneration and age-related degeneration, despite challenges in safety and production costs.

9 Sep 2024

New Advances in DEL Technology Facilitate Synthesis of Large, Complex Molecules

These days, remarkable new medical treatments are all the rage. One such treatment is personalized cancer therapy, which uses antibodies or immune cells that have been altered.

4 Sep 2024

Single-Cell Sequencing Reveals Mechanism of Coronary Artery Formation

The process by which new arteries develop in the heart has been clarified by a group under the direction of Dr. Elena Cano at the Integrative Vascular Biology Lab of Professor Holger Gerhardt at the Max Delbrück Center in Berlin.

2 Sep 2024

Microbiotica Secures Approvals to Begin Clinical Studies in EU and UK for New Microbiome Medicines

Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1) and ulcerative colitis (COMPOSER-1) in selected EU countries and the UK. Both studies are due to start shortly, with initial data readouts expected by the end of 2025.

30 Aug 2024

European Commission Approves Erdafitinib for Advanced Urothelial Carcinoma

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA®▼(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment setting.

30 Aug 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Nutrient Deprivation Strategy Kills Breast Cancer Cells by Blocking Adaptive Pathways

Cancer cells have voracious appetites. And there are certain nutrients they can't live without. Scientists have long hoped they might stop tumors in their tracks by cutting off an essential part of cancer cells' diet. But these cells are crafty and often find a new way to get what they need. How? By reprogramming their metabolism and switching to backup food supplies.

29 Aug 2024

RNA Interference Drugs Offer Faster, More Effective Alternative to Traditional Drug Discovery

Alnylam's RNA interference platform accelerates drug discovery by targeting RNA transcripts, addressing complex diseases with innovative therapeutic strategies.

28 Aug 2024

Clinical Trials Supported by Genetics Show Higher Success Rates

Analyzing 28,561 discontinued trials, the study reveals safety and efficacy concerns as major discontinuation factors, with genetics playing a crucial role.

23 Aug 2024

Efficacy News and Research

African Wormwood Identified as Potential Weapon Against Drug-Resistant Tuberculosis

Bacterial Gene Expression Drives the Evolution of Antibiotic Resistance

CAR-NKT Cells Show Promise in Overcoming Solid Tumor Barriers

Fighting Drug-Resistant TB with a Novel Antibiotic

Aidian is Now An IVDR Certified Company

ERGA Pilot Project Unites Scientists to Deliver High-Quality Genomes

Modified Nucleotides Boost saRNA Vaccine Efficacy and Protection Against SARS-CoV-2

Lipids Found to Play Key Role in Cancer Immune Evasion

Innovative Approach Supercharges T Cells by Transferring Healthy Mitochondria

Developing Techniques for Imaging Biomolecules

Breakthrough Nanoparticle Therapy Boosts Immune Response Against Aggressive Pancreatic Cancer

From Bone Regeneration to Heart Repair: Stem Cell Transplantation Paves the Way for New Medical Frontiers

New Advances in DEL Technology Facilitate Synthesis of Large, Complex Molecules

Single-Cell Sequencing Reveals Mechanism of Coronary Artery Formation

Microbiotica Secures Approvals to Begin Clinical Studies in EU and UK for New Microbiome Medicines

European Commission Approves Erdafitinib for Advanced Urothelial Carcinoma

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Nutrient Deprivation Strategy Kills Breast Cancer Cells by Blocking Adaptive Pathways

RNA Interference Drugs Offer Faster, More Effective Alternative to Traditional Drug Discovery

Clinical Trials Supported by Genetics Show Higher Success Rates

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics